Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

Maesaka, K; Sakamori, R; Yamada, R; Tahata, Y; Imai, Y; Ohkawa, K; Miyazaki, M; Mita, E; Ito, T; Hagiwara, H; Yakushijin, T; Kodama, T; Hikita, H; Tatsumi, T; Takehara, T

Takehara, T (通讯作者)，Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.

HEPATOLOGY RESEARCH, 2022; 52 (3): 298

Abstract

Background Atezolizumab plus bevacizumab was approved for hepatocellular carcinoma (HCC) patients in 2020, but treatment outcomes of atezolizumab plus......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索